Asset Details
Do you wish to reserve the book?
BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes
Do you wish to request the book?
BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes
2023
Overview
Breast cancer is among the most common malignant cancers in women. B‐cell‐specific Moloney murine leukemia virus integration site 1 (BMI‐1) is a transcriptional repressor that has been shown to be involved in tumorigenesis, the cell cycle, and stem cell maintenance. In our study, increased expression of BMI‐1 was found in both human triple negative breast cancer and luminal A‐type breast cancer tissues compared with adjacent tissues. We also found that knockdown of BMI‐1 significantly suppressed cell proliferation and migration in vitro and in vivo. Further mechanistic research demonstrated that BMI‐1 directly bound to the promoter region of CDKN2D/BRCA1 and inhibited its transcription in MCF‐7/MDA‐MB‐231. More importantly, we discovered that knockdown of CDKN2D/BRCA1 could promote cell proliferation and migration after repression by PTC‐209. Our results reveal that BMI‐1 transcriptionally suppressed BRCA1 in TNBC cell lines whereas, in luminal A cell lines, CDKN2D was the target gene. This provides a reference for the precise treatment of different types of breast cancer in clinical practice. BMI‐1 promotes proliferation and migration via transcriptional inhibition of cyclin‐dependent kinase inhibitor 2D (CDKN2D) in luminal A‐type breast cancer but via transcriptional inhibition of breast cancer susceptibility gene 1 (BRCA1) in TNBC.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
